Carboplatin-Etoposide Chemotherapy (CB-ET) for Patients Diagnosed with Advanced Extra-Pulmonary (EP) Poorly Differentiated (PD) Neuroendocrine Carcinoma (NEC): Findings from a European Neuroendocrine Tumor Society Centre of Excellence

被引：0
|
作者：
Frizziero, M. [1 ]
Lamarca, A. [1 ]
Kordatou, Z. [1 ]
Barriuso, J. [1 ,2 ]
Nuttall, C. [1 ]
McNamara, M. G. [1 ,2 ]
Hubner, R. [1 ]
Mansoor, W. [1 ]
Manoharan, P. [1 ]
Valle, J. [1 ,2 ]
机构：
[1] Christie NHS Fdn Trust, Manchester, Lancs, England
[2] Univ Manchester, Div Canc Sci, Manchester, Lancs, England
来源：
NEUROENDOCRINOLOGY | 2018年 / 106卷
关键词：
carboplatin-etoposide; poorly differentiated extra-pulmonary neuroendocrine carcinoma; activity; efficacy; safety;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
D21
引用
收藏
页码：77 / 77
页数：1
相关论文
共 9 条
  • [1] Carboplatin (CB) combined with oral or intravenous (IV) etoposide (ET) for advanced extra-pulmonary (EP) poorly differentiated (PD) neuroendocrine carcinoma (NEC): Real-world findings from two European neuroendocrine tumour society centres of excellence
    Frizziero, M.
    Spada, F.
    Lamarca, A.
    Kordatou, Z.
    Barriuso, J.
    Nuttall, C.
    McNamara, M. G.
    Hubner, R.
    Mansoor, W.
    Manoharan, P.
    Fazio, N.
    Valle, J. W.
    [J]. ANNALS OF ONCOLOGY, 2018, 29 : 472 - 472
  • [2] Second-Line Treatment in Patients (pts) with Advanced Extra-Pulmonary Poorly Differentiated Neuroendocrine Carcinoma (EP-PD-NEC): A Systematic Review and Meta-Analysis
    McNamara, M. G.
    Frizziero, M.
    Jacobs, T.
    Lamarca, A.
    Hubner, R.
    Valle, J. W.
    Amir, E.
    [J]. NEUROENDOCRINOLOGY, 2019, 108 : 188 - 188
  • [3] Impact of Small Cell (SC) versus (vs.) Non-Small Cell (nSC) Morphology on Outcomes of Patients (pts) with Extra-Pulmonary, Poorly Differentiated Neuroendocrine Carcinoma (EP-PD-NEC)
    Zaninotto, E.
    Frizziero, M.
    Durand, A.
    Taboada, R. G.
    Luchini, C.
    Oliveira, P.
    Hervieu, V
    Claro, L. C. L.
    Cingarlini, S.
    Walter, T.
    Riechelmann, R.
    McNamara, M.
    [J]. NEUROENDOCRINOLOGY, 2020, 110 : 244 - 244
  • [4] Urgent need for consensus: international survey of clinical practice exploring use of platinum-etoposide chemotherapy for advanced extra-pulmonary high grade neuroendocrine carcinoma (EP-G3-NEC)
    Lamarca, A.
    Frizziero, M.
    Barriuso, J.
    McNamara, M. G.
    Hubner, R. A.
    Valle, J. W.
    [J]. CLINICAL & TRANSLATIONAL ONCOLOGY, 2019, 21 (07): : 950 - 953
  • [5] Urgent need for consensus: international survey of clinical practice exploring use of platinum-etoposide chemotherapy for advanced extra-pulmonary high grade neuroendocrine carcinoma (EP-G3-NEC)
    A. Lamarca
    M. Frizziero
    J. Barriuso
    M. G. McNamara
    R. A. Hubner
    J. W. Valle
    [J]. Clinical and Translational Oncology, 2019, 21 : 950 - 953
  • [6] NET-02: A multicenter, randomized, phase II trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients (pts) with progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma (PD-EP-NEC).
    McNamara, Mairead Geraldine
    Swain, Jayne
    Craig, Zoe
    Sharma, Rohini
    Faluyi, Olusola Olusesan
    Wadsley, Jonathan
    Morgan, Carys
    Wall, Lucy R.
    Chau, Ian
    Reed, Nick
    Sarker, Debashis
    Margetts, Jane
    Krell, Daniel
    Cave, Judith
    Sharmila, Sothi
    Anthoney, Alan
    Patel, Alkesh
    Lamarca, Angela
    Hubner, Richard A.
    Valle, Juan W.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [7] NET-02: A multi-center, randomised, phase II trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients (pts) with progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma (PD-EP-NEC).
    McNamara, Mairead Geraldine
    Swain, Jayne
    Craig, Zoe
    Wadsley, Jonathan
    Reed, Nicholas
    Faluyi, Olusola Olusesan
    Lamarca, Angela
    Hubner, Richard
    Mansoor, Wasat
    Sarker, Debashis
    Howard, Helen C.
    Cairns, David A.
    Meyer, Tim
    Valle, Juan W.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [8] Health-related quality of life (HRQoL) in patients (pts) with progressive, poorly differentiated, extra-pulmonary neuroendocrine carcinoma (PD-EP-NEC) enrolled in NET-02: A phase II trial of liposomal irinotecan (nal-IRI)/5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy
    Craig, Zoe
    Swain, Jayne
    Sharma, Rohini
    Faluyi, Olusola Olusesan
    Wadsley, Jonathan
    Morgan, Carys
    Wall, Lucy R.
    Chau, Ian
    Reed, Nicholas Simon
    Sarker, Debashis
    Margetts, Jane
    Krell, Daniel
    Cave, Judith
    Sharmila, Sothi
    Anthoney, Alan
    Patel, Alkesh
    Lamarca, Angela
    Hubner, Richard A.
    Valle, Juan W.
    McNamara, Mairead Geraldine
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (28) : 293 - 293
  • [9] The clinical utility of plasma cell-free DNA (cfDNA) in NET-02: Randomised, phase II trial of liposomal irinotecan (nal-IRI)/5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line (2L) therapy in patients (pts) with progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma (PD-EP-NEC).
    McNamara, Mairead Geraldine
    Pearce, Simon
    Swain, Jayne
    Halford, Mollie Anne
    Sharma, Rohini
    Faluyi, Olusola Olusesan
    Wadsley, Jonathan
    Morgan, Carys
    Wall, Lucy R.
    Chau, Ian
    Reed, Nick
    Sarker, Debashis
    Margetts, Jane
    Anthoney, Alan
    Oughton, Jamie B.
    Lamarca, Angela
    Hubner, Richard
    Rothwell, Dominic G.
    Valle, Juan W.
    Clipson, Alexandra
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
1